Cargando…

New treatment options for lupus – a focus on belimumab

Belimumab is the first biologic approved for patients with systemic lupus erythematosus (SLE). Belimumab is the first of a new class of drug targeting B cell-stimulating factors or their receptors to reach the market. Its target, BLyS, also known as BAFF (B cell-activating factor from the tumor necr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiche, Laurent, Jourde, Noémie, Thomas, Guillemette, Bardin, Nathalie, Bornet, Charleric, Darque, Albert, Mancini, Julien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3277870/ https://www.ncbi.nlm.nih.gov/pubmed/22346356 http://dx.doi.org/10.2147/TCRM.S19819

Ejemplares similares

Brincidofovir Use after Foscarnet Crystal Nephropathy in a Kidney Transplant Recipient with Multiresistant Cytomegalovirus Infection
por: Vial, Romain, et al.
Publicado: (2017)

Belimumab for systemic lupus erythematosus – Focus on lupus nephritis
por: Plüß, Marlene, et al.
Publicado: (2022)

Weaning Maintenance Therapy in Lupus Nephritis: For Whom, When, and How?
por: Jourde-Chiche, Noémie, et al.
Publicado: (2023)

Serum GlycA Level Is Elevated in Active Systemic Lupus Erythematosus and Correlates to Disease Activity and Lupus Nephritis Severity
por: Dierckx, Tim, et al.
Publicado: (2020)

Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab
por: Guzman, Marla, et al.
Publicado: (2020)

Original Approach for Automated Quantification of Antinuclear Autoantibodies by Indirect Immunofluorescence
por: Bertin, Daniel, et al.
Publicado: (2013)

An update on belimumab for the treatment of lupus
por: Thanou-Stavraki, Aikaterini, et al.
Publicado: (2011)

Belimumab in systemic lupus erythematosus
por: Vilas-Boas, Andreia, et al.
Publicado: (2015)

Belimumab in Systemic Lupus Erythematosus
por: Srivastava, Ankita
Publicado: (2016)

Association between the Presence of Autoantibodies Targeting Ficolin-3 and Active Nephritis in Patients with Systemic Lupus Erythematosus
por: Plawecki, Maëlle, et al.
Publicado: (2016)

Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus
por: Dimelow, Richard, et al.
Publicado: (2020)

Systemic Lupus Erythematosus and Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Overlap Syndrome in Patients With Biopsy-Proven Glomerulonephritis
por: Jarrot, Pierre-Andre, et al.
Publicado: (2016)

The Place of Immunotherapy in the Management of HCV-Induced Vasculitis: An Update
por: Chiche, Laurent, et al.
Publicado: (2012)

Endothelial Toxicity of High Glucose and its by-Products in Diabetic Kidney Disease
por: Dou, Laetitia, et al.
Publicado: (2019)

Reply to ‘Kidney involvement in hereditary transthyretin amyloidosis: is there a role for cystatin C?’
por: Solignac, Justine, et al.
Publicado: (2022)

De novo lupus nephritis during treatment with belimumab
por: Parodis, Ioannis, et al.
Publicado: (2020)

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus
por: Urowitz, Murray B., et al.
Publicado: (2022)

Subcutaneous formulation of belimumab in treatment of systemic lupus erythematosus: a critical review with focus on safety and satisfaction
por: Ahmed, Hamdy MA, et al.
Publicado: (2018)

Proliferative lupus nephritis in the absence of overt systemic lupus erythematosus: A historical study of 12 adult patients
por: Touzot, Maxime, et al.
Publicado: (2017)

Belimumab: First targeted biological treatment for systemic lupus erythematosus
por: Dubey, Ashok K., et al.
Publicado: (2011)

Efficacy of novel monoclonal antibody belimumab in the treatment of lupus nephritis
por: Frieri, Marianne, et al.
Publicado: (2015)

Clinical Efficacy of Routinely Administered Belimumab on Proteinuria and Neuropsychiatric Lupus
por: Plüß, Marlene, et al.
Publicado: (2020)

Belimumab in Lupus Nephritis: A Systematic Review and Meta-Analysis
por: Shrestha, Sanjeev, et al.
Publicado: (2021)

The Role of Belimumab in Systemic Lupus Erythematosis: A Systematic Review
por: Joy, Ashna, et al.
Publicado: (2022)

Urine proteomic insights from the belimumab in lupus nephritis trial
por: Weeding, Emma, et al.
Publicado: (2022)

Predictive Factors of the Use of Rituximab and Belimumab in Spanish Lupus Patients
por: Capdevila, O., et al.
Publicado: (2023)

Effect of Belimumab on Preventing de novo Renal Lupus Flares
por: Parodis, Ioannis, et al.
Publicado: (2023)

Urinary Peptides as Potential Non-Invasive Biomarkers for Lupus Nephritis: Results of the Peptidu-LUP Study
por: Tailliar, Maxence, et al.
Publicado: (2021)

Real life experience on the effect of Belimumab in patients with active systemic lupus
por: Scheinberg, Morton, et al.
Publicado: (2014)

Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus Erythematosus
por: Zhou, Xuan, et al.
Publicado: (2021)

Belimumab in childhood systemic lupus erythematosus: A review of available data
por: Chen, Feng, et al.
Publicado: (2022)

Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment
por: Kirou, Kyriakos A., et al.
Publicado: (2022)

Treatment Using Both Voclosporin and Belimumab in Four Patients With Lupus Nephritis
por: Baum, Rebecca, et al.
Publicado: (2023)

Health Technology Assessment of Belimumab: A New Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
por: Specchia, Maria Lucia, et al.
Publicado: (2014)

Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis
por: Arvaniti, Pinelopi, et al.
Publicado: (2020)

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
por: van Vollenhoven, Ronald F, et al.
Publicado: (2012)

Kidney involvement in hereditary transthyretin amyloidosis: a cohort study of 103 patients
por: Solignac, Justine, et al.
Publicado: (2022)

Pharmacogenetic analysis of belimumab fails to identify robust genetic predictors of efficacy in lupus
por: St Jean, Pamela L., et al.
Publicado: (2019)

Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2020)

Budget Impact Analysis Of Subcutaneous Belimumab In Patients With Systemic Lupus Erythematosus In Spain
por: Cevey, Maria, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_s89b0cdg9idf092gs1popmgq2q